To explore the effect of new auxiliary chemotherapy before operation on treating local mammary cancer of late stage and prolonging the life of the cancer patients.

Objective To evaluate the clinical value of neoadjuvant chemotherapy for breast cancer on pathological stage and designing of therapy plan.

Conclusions Adjuvant chemotherapy containing paclitaxel can improve the disease-free survival of breast cancer with HER-2 positive, especially for the patients with er and pr negative.